Cargando…
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden
IMPORTANCE: The KEYNOTE-177 trial demonstrated that patients with metastatic colorectal cancer (MCRC) with high microsatellite instability (MSI-H) and/or mismatch repair deficiency (DMMR) have better outcomes when receiving first-line immune checkpoint inhibitors (ICIs) compared with chemotherapy. D...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871803/ https://www.ncbi.nlm.nih.gov/pubmed/36689222 http://dx.doi.org/10.1001/jamanetworkopen.2022.52244 |
_version_ | 1784877262256996352 |
---|---|
author | Quintanilha, Julia C. F. Graf, Ryon P. Fisher, Virginia A. Oxnard, Geoffrey R. Ellis, Haley Panarelli, Nicole Lin, Douglas I. Li, Gerald Huang, Richard S. P. Ross, Jeffrey S. Myer, Parvathi A. Klempner, Samuel J. |
author_facet | Quintanilha, Julia C. F. Graf, Ryon P. Fisher, Virginia A. Oxnard, Geoffrey R. Ellis, Haley Panarelli, Nicole Lin, Douglas I. Li, Gerald Huang, Richard S. P. Ross, Jeffrey S. Myer, Parvathi A. Klempner, Samuel J. |
author_sort | Quintanilha, Julia C. F. |
collection | PubMed |
description | IMPORTANCE: The KEYNOTE-177 trial demonstrated that patients with metastatic colorectal cancer (MCRC) with high microsatellite instability (MSI-H) and/or mismatch repair deficiency (DMMR) have better outcomes when receiving first-line immune checkpoint inhibitors (ICIs) compared with chemotherapy. Data on performance of ICIs in patients with MCRC in standard practice settings remain limited, and direct MMR vs MSI outcome association comparisons are lacking. OBJECTIVE: To validate MSI (determined by next-generation sequencing [NGS]) as a biomarker of ICI effectiveness among patients with MCRC in standard practice settings and examine the association of MSI assessed by NGS, DMMR by immunohistochemistry, and tumor mutational burden (cutoff, 10 mutations/megabase) with ICI outcomes. DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness research study of outcomes in prospectively defined biomarker subgroups used data from a deidentified clinicogenomic database and included patients who received Foundation Medicine testing (FoundationOne or FoundationOne CDx) during routine clinical care at approximately 280 US academic or community-based cancer clinics between March 2014 and December 2021. The population included 1 cohort of patients with MSI-H MCRC who received first-line ICIs or chemotherapy and a second cohort who received ICIs in any line of therapy (LOT) for biomarker examination. EXPOSURES: ICI therapy or chemotherapy assigned at physician discretion without randomization. MAIN OUTCOMES AND MEASURES: The main outcomes were time to next treatment (TTNT), progression-free survival (PFS), and overall survival (OS). Hazard ratios were adjusted for known prognostic imbalances. Comparisons of explanatory power used the likelihood ratio test. RESULTS: A total of 138 patients (median age, 67.0 years [IQR, 56.2-74.0 years]; 73 [52.9%] female) with MSI-H MCRC received first-line ICIs or chemotherapy. A total of 182 patients (median age, 64.5 years [IQR, 55.2-72.0]; 98 [53.8%] female) received ICIs in any LOT. Patients receiving first-line ICIs vs chemotherapy had longer TTNT (median, not reached [NR] vs 7.23 months [IQR, 6.21-9.72 months]; adjusted hazard ratio [AHR], 0.17; 95% CI, 0.08-0.35; P < .001), PFS (median, 24.87 months [IQR, 19.10 months to NR] vs 5.65 months [IQR, 4.70-8.34 months]; AHR, 0.31; 95% CI, 0.18-0.52; P < .001), and OS (median, NR vs 24.1 months [IQR, 13.90 months to NR]; HR, 0.45; 95% CI, 0.23-0.88; P = .02). MSI added to DMMR better anticipated TTNT and PFS in patients receiving ICIs than DMMR alone. The same was not observed when DMMR evaluation was added to MSI. CONCLUSIONS AND RELEVANCE: In this comparative effectiveness research study, MSI assessed by NGS robustly identified patients with favorable outcomes on first-line ICIs vs chemotherapy and appeared to better anticipate ICI outcomes compared with DMMR. |
format | Online Article Text |
id | pubmed-9871803 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-98718032023-02-08 Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden Quintanilha, Julia C. F. Graf, Ryon P. Fisher, Virginia A. Oxnard, Geoffrey R. Ellis, Haley Panarelli, Nicole Lin, Douglas I. Li, Gerald Huang, Richard S. P. Ross, Jeffrey S. Myer, Parvathi A. Klempner, Samuel J. JAMA Netw Open Original Investigation IMPORTANCE: The KEYNOTE-177 trial demonstrated that patients with metastatic colorectal cancer (MCRC) with high microsatellite instability (MSI-H) and/or mismatch repair deficiency (DMMR) have better outcomes when receiving first-line immune checkpoint inhibitors (ICIs) compared with chemotherapy. Data on performance of ICIs in patients with MCRC in standard practice settings remain limited, and direct MMR vs MSI outcome association comparisons are lacking. OBJECTIVE: To validate MSI (determined by next-generation sequencing [NGS]) as a biomarker of ICI effectiveness among patients with MCRC in standard practice settings and examine the association of MSI assessed by NGS, DMMR by immunohistochemistry, and tumor mutational burden (cutoff, 10 mutations/megabase) with ICI outcomes. DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness research study of outcomes in prospectively defined biomarker subgroups used data from a deidentified clinicogenomic database and included patients who received Foundation Medicine testing (FoundationOne or FoundationOne CDx) during routine clinical care at approximately 280 US academic or community-based cancer clinics between March 2014 and December 2021. The population included 1 cohort of patients with MSI-H MCRC who received first-line ICIs or chemotherapy and a second cohort who received ICIs in any line of therapy (LOT) for biomarker examination. EXPOSURES: ICI therapy or chemotherapy assigned at physician discretion without randomization. MAIN OUTCOMES AND MEASURES: The main outcomes were time to next treatment (TTNT), progression-free survival (PFS), and overall survival (OS). Hazard ratios were adjusted for known prognostic imbalances. Comparisons of explanatory power used the likelihood ratio test. RESULTS: A total of 138 patients (median age, 67.0 years [IQR, 56.2-74.0 years]; 73 [52.9%] female) with MSI-H MCRC received first-line ICIs or chemotherapy. A total of 182 patients (median age, 64.5 years [IQR, 55.2-72.0]; 98 [53.8%] female) received ICIs in any LOT. Patients receiving first-line ICIs vs chemotherapy had longer TTNT (median, not reached [NR] vs 7.23 months [IQR, 6.21-9.72 months]; adjusted hazard ratio [AHR], 0.17; 95% CI, 0.08-0.35; P < .001), PFS (median, 24.87 months [IQR, 19.10 months to NR] vs 5.65 months [IQR, 4.70-8.34 months]; AHR, 0.31; 95% CI, 0.18-0.52; P < .001), and OS (median, NR vs 24.1 months [IQR, 13.90 months to NR]; HR, 0.45; 95% CI, 0.23-0.88; P = .02). MSI added to DMMR better anticipated TTNT and PFS in patients receiving ICIs than DMMR alone. The same was not observed when DMMR evaluation was added to MSI. CONCLUSIONS AND RELEVANCE: In this comparative effectiveness research study, MSI assessed by NGS robustly identified patients with favorable outcomes on first-line ICIs vs chemotherapy and appeared to better anticipate ICI outcomes compared with DMMR. American Medical Association 2023-01-23 /pmc/articles/PMC9871803/ /pubmed/36689222 http://dx.doi.org/10.1001/jamanetworkopen.2022.52244 Text en Copyright 2023 Quintanilha JCF et al. JAMA Network Open. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the CC-BY-NC-ND License. |
spellingShingle | Original Investigation Quintanilha, Julia C. F. Graf, Ryon P. Fisher, Virginia A. Oxnard, Geoffrey R. Ellis, Haley Panarelli, Nicole Lin, Douglas I. Li, Gerald Huang, Richard S. P. Ross, Jeffrey S. Myer, Parvathi A. Klempner, Samuel J. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden |
title | Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden |
title_full | Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden |
title_fullStr | Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden |
title_full_unstemmed | Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden |
title_short | Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden |
title_sort | comparative effectiveness of immune checkpoint inhibitors vs chemotherapy in patients with metastatic colorectal cancer with measures of microsatellite instability, mismatch repair, or tumor mutational burden |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871803/ https://www.ncbi.nlm.nih.gov/pubmed/36689222 http://dx.doi.org/10.1001/jamanetworkopen.2022.52244 |
work_keys_str_mv | AT quintanilhajuliacf comparativeeffectivenessofimmunecheckpointinhibitorsvschemotherapyinpatientswithmetastaticcolorectalcancerwithmeasuresofmicrosatelliteinstabilitymismatchrepairortumormutationalburden AT grafryonp comparativeeffectivenessofimmunecheckpointinhibitorsvschemotherapyinpatientswithmetastaticcolorectalcancerwithmeasuresofmicrosatelliteinstabilitymismatchrepairortumormutationalburden AT fishervirginiaa comparativeeffectivenessofimmunecheckpointinhibitorsvschemotherapyinpatientswithmetastaticcolorectalcancerwithmeasuresofmicrosatelliteinstabilitymismatchrepairortumormutationalburden AT oxnardgeoffreyr comparativeeffectivenessofimmunecheckpointinhibitorsvschemotherapyinpatientswithmetastaticcolorectalcancerwithmeasuresofmicrosatelliteinstabilitymismatchrepairortumormutationalburden AT ellishaley comparativeeffectivenessofimmunecheckpointinhibitorsvschemotherapyinpatientswithmetastaticcolorectalcancerwithmeasuresofmicrosatelliteinstabilitymismatchrepairortumormutationalburden AT panarellinicole comparativeeffectivenessofimmunecheckpointinhibitorsvschemotherapyinpatientswithmetastaticcolorectalcancerwithmeasuresofmicrosatelliteinstabilitymismatchrepairortumormutationalburden AT lindouglasi comparativeeffectivenessofimmunecheckpointinhibitorsvschemotherapyinpatientswithmetastaticcolorectalcancerwithmeasuresofmicrosatelliteinstabilitymismatchrepairortumormutationalburden AT ligerald comparativeeffectivenessofimmunecheckpointinhibitorsvschemotherapyinpatientswithmetastaticcolorectalcancerwithmeasuresofmicrosatelliteinstabilitymismatchrepairortumormutationalburden AT huangrichardsp comparativeeffectivenessofimmunecheckpointinhibitorsvschemotherapyinpatientswithmetastaticcolorectalcancerwithmeasuresofmicrosatelliteinstabilitymismatchrepairortumormutationalburden AT rossjeffreys comparativeeffectivenessofimmunecheckpointinhibitorsvschemotherapyinpatientswithmetastaticcolorectalcancerwithmeasuresofmicrosatelliteinstabilitymismatchrepairortumormutationalburden AT myerparvathia comparativeeffectivenessofimmunecheckpointinhibitorsvschemotherapyinpatientswithmetastaticcolorectalcancerwithmeasuresofmicrosatelliteinstabilitymismatchrepairortumormutationalburden AT klempnersamuelj comparativeeffectivenessofimmunecheckpointinhibitorsvschemotherapyinpatientswithmetastaticcolorectalcancerwithmeasuresofmicrosatelliteinstabilitymismatchrepairortumormutationalburden |